Organisation paid for research Program year 2025 Source: CMS Open Payments

USC General Depository

Neither a doctor nor a teaching hospital

Research payments

$383,527

77 payments

Through program year 2025, USC General Depository is reported as receiving $383,527 in research payments, across 77 payments.

By program year

3 rows

Year	Kind	Amount	Payments
2025	Research	$128,370	41
2024	Research	$98,315	17
2023	Research	$156,842	19

Breakdown

Who paid Research payments · program years 2023–2025

Pfizer Inc. $326,117 46 payments
Sanofi US Services Inc. $38,928 30 payments
Syndax Pharmaceuticals, Inc. $18,482 1 payment

Studies the money was for Research payments · program years 2023–2025

An Openlabel Multicenter Randomized Phase 3 Study of Firstline Encorafenib Plus Cetuximab With Or Without Chemotherapy Versus Standard of Care Therapy With A Safety Leadin of Encorafenib and Cetuximab Plus Chemotherapy in Participants With Metastatic Braf V600emutant Colorectal Cancer $146,111 23 payments
A Phase 2 Doubleblind Randomized Placebocontrolled 4Arm Study to Investigate Symptoms Function Healthrelated Quality of Life and Safety With Repeated Subcutaneous Administration of Ponsegromab Versus Placebo in Adult Participants With Heart Failure $68,441 12 payments
Ph3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With Open Label Extension to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP) $38,928 30 payments
An Interventional Openlabel Randomized Multicenter Phase 3 Study of Pf07220060 Plus Fulvestrant Compared to Investigators Choice of Therapy in Participants Over 18 Years of Age With Hormone Receptorpositive Her2negative Advancedmetastatic Breast Cancer Whose Disease Progressed After Prior CDK 46 Inhibitor Based Therapy $34,822 5 payments
A Twopart Phase 1AB Openlabel Multicenter Trial Evaluating Pharmacokinetics Safety and Efficacy of PF 07284890 Arry 461 in Participants With Braf V600 Mutant Solid Tumors With and Without Brain Involvement $31,232 2 payments
An Interventional Openlabel Randomized Multicenter Phase 3 Study of Pf07220060 Plus Letrozole Compared to Cdk46 Inhibitor Plus Letrozole in Participants Over 18 Years of Age With Hormone Receptor Hrpositive Her2negative Advancedmetastatic Breast Cancer Who Have Not Received Any Prior Systemic Anticancer Treatment for Advancedmetastatic Disease Fourlight3 $22,755 3 payments
A Phase 1AB Openlabel Master Study of Pf07799544 As A Singleagent and in Combination With Other Targeted Agents in Participants With Advanced Solid Tumors $22,755 1 payment
AGAVE-201, A Phase 2, Open-label, Randomized, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of Axatilimab at 3 Different Doses in Patients With Recurrent or Refractory Active Chronic Graft Versus Host Disease Who Have Received at Least 2 Lines of Systemic Therapy $18,482 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.